
Swetha Kambhampati
285 posts

Swetha Kambhampati
@SwethaKMD
Assistant Professor at City of Hope; Alum: UCSF heme/onc, Hopkins IM, Stanford Med; Interested in lymphoma and CART














#NEWS: Today, we announced the primary overall survival (OS) analysis results, a key secondary endpoint, of our Phase 3 study of CAR T-cell therapy for initial treatment of relapsed/refractory large B-cell lymphoma.


🔊Coming Thursday, 3/23: An all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @SwethaKMD of @cityofhope and Nikhil Thiruvengadam, MD, of @UCSF about modeling the cost effectiveness of pola-R-CHP in relation to other DLBCL therapies. @SocietyofHemOnc

🔊Coming Thursday, 3/23: An all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @SwethaKMD of @cityofhope and Nikhil Thiruvengadam, MD, of @UCSF about modeling the cost effectiveness of pola-R-CHP in relation to other DLBCL therapies. @SocietyofHemOnc






Amazing week with LRF LSRMP at Lake Las Vegas. Great protocol development. Meeting mentors and colleagues was invaluable! @lymphoma @OSUHematology